Juniper Pharmaceuticals, Inc. Common Stock
JNP
JNP was delisted on the 13th of August, 2018.
30 hedge funds and large institutions have $10.1M invested in Juniper Pharmaceuticals, Inc. Common Stock in 2013 Q3 according to their latest regulatory filings, with 30 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$1.9M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.61M |
| 3 |
Renaissance Technologies
New York
|
+$1.24M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$609K |
| 5 |
NI
Numeric Investors
Boston,
Massachusetts
|
+$534K |
Top Sellers
JNP Hedge Fund Activity: Q3 2013 in Review
30 of the 3,085 institutional investors tracked by Wall St. Rank reported a position in Juniper Pharmaceuticals, Inc. Common Stock (JNP) for Q3 2013, worth a combined $10.1M.
Buyers outnumbered sellers: 30 funds opened new JNP positions and 0 closed out — a net gain of 30 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was BlackRock Institutional Trust, opening a new position worth an estimated $1.9M.
- 30 institutional investors held Juniper Pharmaceuticals, Inc. Common Stock (JNP) as of Q3 2013, up from 0 in Q2 2013.
- Funds reported $10.1M of Juniper Pharmaceuticals, Inc. Common Stock stock for Q3 2013.
- 30 funds opened new Juniper Pharmaceuticals, Inc. Common Stock positions in Q3 2013 and 0 closed out, a net change of +30 holders.
- The largest Juniper Pharmaceuticals, Inc. Common Stock buyer in Q3 2013 was BlackRock Institutional Trust, an estimated $1.9M added.
Based on aggregated 13F filings for Q3 2013.